Limiting systemic plasminogenolysis reduces the bleeding potential for tissue-type plasminogen activators but not for streptokinase.
Clinical experience suggests that thrombolytic-induced bleeding is associated with systemic activation of the thrombolytic system. Using fibrin specific variants of tissue-type plasminogen activator (t-PA) and making use of the apparent fibrin specificity of streptokinase (SK) in the rabbit we tested the hypothesis that minimizing systemic plasmin production and fibrinogenolysis will decrease hemorrhages in models of peripheral bleeding and embolic stroke. t-PA consumed 51% of the available fibrinogen; caused cerebral bleeds and increased peripheral bleeding time. Fibrin-specific variants of t-PA depleted less than 20% of the fibrinogen and did not cause peripheral or cerebral bleeding. However, an equipotent dose of SK converted only 12% of the available fibrinogen but increased bleeding time and caused hemorrhagic conversion in 75% of embolic stroke model animals treated. The data suggest that bleeding associated with tissue-type plasminogen activators is linked to systemic plasmin generation and subsequent fibrinogenolysis. This hypothesis does not explain the mechanism(s) of SK-induced bleeding.
Thomas
G R
GR
Department of Cardiovascular Research, Genentech Inc., South San Francisco, CA 94080, USA. thomas.roger@gene.com
Thibodeaux
H
H
Errett
C J
CJ
Badillo
J M
JM
Wu
D T
DT
Refino
C J
CJ
Keyt
B A
BA
Bennett
W F
WF
D000818:Animals; D001760:Bleeding Time; D005337:Fibrin / Q000378:metabolism; D006470:Hemorrhage / Q000097:blood* / Q000517:prevention & control; D010958:Plasminogen / Q000378:metabolism*; D011817:Rabbits; D013300:Streptokinase / Q000378:metabolism / Q000627:therapeutic use*; D010959:Tissue Plasminogen Activator / Q000097:blood*
D005337:Fibrin; D010958:Plasminogen; D013300:Streptokinase; D010959:Tissue Plasminogen Activator